Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
16/06/26	0.3295 kr	+6.29%	7,401,845
15/06/26	0.3100 kr	+6.90%	2,887,648
12/06/26	0.2900 kr	-3.33%	9,683,883
11/06/26	0.3000 kr	-9.09%	21,059,360
10/06/26	0.3300 kr	+10.74%	37,858,430

Real-time Oslo Bors

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Oslo Bors Other stock markets 18:45:00 16/06/2026 +04			5-day change	1st Jan Change
0.3295 ^NOK	+6.29%		+2.97%	-89.89%

06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026

Market Cap	92.42M 9.74M 8.4M 7.73M 7.26M 13.63M 921M 13.77M 91.37M 35.6M 451M 36.57M 35.79M 1.56B	P/E Ratio 2026 *	-0.82x	P/E Ratio 2027 *	-1.11x
Enterprise Value	128M 13.54M 11.67M 10.74M 10.09M 18.94M 1.28B 19.14M 127M 49.46M 627M 50.81M 49.73M 2.17B	EV / Sales 2026 *	-	EV / Sales 2027 *	26.1x
Free-Float	51.56%	Yield 2026 *	-	Yield 2027 *	-

06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026
05-15	Lifecare ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-15	Lifecare Q1 operating loss NOK 31.5 mln	RE
04-23	Lifecare ASA Approves Board Appointments	CI
03-26	Lifecare ASA Announces Operational Restructuring And Centralization Of Operations	CI
03-26	Lifecare ASA Announces Discontinuation of the Business Operations of Lifecare Germany GmbH	CI
03-26	Lifecare ASA to Close German Operations, Consolidate Activities Under Planned Centralization	MT
03-16	Lifecare Chief Scientific Officer to Step Down	MT
03-14	Andreas Pfützner to Step Down as Chief Scientific Officer of Lifecare ASA	CI
03-10	Lifecare receives regulatory feedback on first-in-human application	RE
03-10	Lifecare ASA Receives Regulatory Feedback on First-in-Human Application	CI
03-05	Lifecare ASA Confirms 12-Week Implant Stability Under Real-Life Conditions And Reduces Durability Risk Ahead Of First-In-Human Study	CI

06-12	Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue	PU
06-10	Lifecare ASA: Mandatory notification of trade	PU
06-10	Lifecare completes first six-month implant evaluation with continued functionality and no adverse biological response	AQ
06-01	Lifecare ASA: Commencement of the Exercise Period for Warrants Series 2 issued in connection with the Rights Issue	PU
05-20	Lifecare ASA: Mandatory notification of trade	PU

Lifecare ASA Stock

Stocks

LIFE

NO0013355859

Biotechnology & Medical Research

Valuation: Lifecare ASA

Chart: Lifecare ASA

Latest news : Lifecare ASA

Last Transcript: Lifecare ASA

Analysts' recommendations: Lifecare ASA

Press Releases: Lifecare ASA

News in other languages: Lifecare ASA

Quotes and Performance

Course Extremes

Managers and Directors: Lifecare ASA

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+6.29%
1 week	+2.97%
Current month	-0.30%
1 month	-12.37%
3 months	-19.83%
6 months	-92.32%
Current year	-89.89%

1 week	0.27	0.42
1 month	0.27	0.42
Current year	0.27	2
1 year	0.27	23.5
3 years	0.27	82.16
5 years	0.27	82.16
10 years	0.27	117

Manager	Title	Age	Since
Joacim Holter CEO	Chief Executive Officer	50	07/09/2020
Petter Nielsen DFI	Director of Finance/CFO	-	01/04/2026
Torsten Ernst PRN	Corporate Officer/Principal	-	01/03/2024

Director	Title	Age	Since
Trine Teigland BRD	Director/Board Member	-	26/06/2020
Morten Foros Krohnstad CHM	Chairman	-	08/05/2021
Lutz Heinemann BRD	Director/Board Member	-	20/11/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIFECARE ASA	+6.29%	+2.97%	-94.85%	-98.67%	9.7M
LONZA GROUP AG	-0.12%	+1.04%	-13.08%	-12.43%	43.58B
REVOLUTION MEDICINES, INC.	-2.07%	+4.95%	+294.64%	+537.49%	34.03B
IQVIA HOLDINGS INC.	+5.77%	-3.92%	+12.37%	-17.16%	29.77B
BEONE MEDICINES AG	+13.09%	-1.69%	-0.29%	+31.68%	29.82B
CELLTRION, INC.	-0.29%	+9.47%	+13.95%	+21.93%	25.42B
ASCENDIS PHARMA A/S	-7.56%	+8.91%	-	-	13.87B
MEDPACE HOLDINGS, INC.	-2.75%	-0.80%	+53.85%	+108.75%	13.35B
EUROFINS SCIENTIFIC SE	-1.04%	-3.33%	+3.98%	+3.91%	12.85B
IONIS PHARMACEUTICALS, INC.	+4.27%	-2.00%	+107.41%	+78.18%	12.22B
Average	+0.31%	+1.51%	+42.00%	+72.63%	21.49B
Weighted average by Cap.	-0.53%	+2.02%	+60.94%	+105.42%

	2026 *	2027 *
Net sales	-	5M 527K 454K 418K 393K 737K 49.84M 745K 4.94M 1.93M 24.41M 1.98M 1.94M 84.58M
Net income	-86M -9.07M -7.81M -7.2M -6.76M -12.68M -857M -12.82M -85.03M -33.12M -420M -34.03M -33.31M -1.45B	-82M -8.65M -7.45M -6.86M -6.44M -12.09M -817M -12.22M -81.07M -31.58M -400M -32.45M -31.76M -1.39B
Net Debt	36M 3.8M 3.27M 3.01M 2.83M 5.31M 359M 5.37M 35.59M 13.87M 176M 14.24M 13.94M 609M	38M 4.01M 3.45M 3.18M 2.99M 5.6M 379M 5.66M 37.57M 14.64M 185M 15.04M 14.72M 643M